Compass Therapeutics clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

1. Notable

   CTX-471 as a Monotherapy or in Combination With Pembrolizumab in…CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

   Reclassified as terminated (was completed)

   Also in this update: Results posted: Oct 9, 2026

   Compass Therapeutics·Phase 1· NCT03881488· Registry history of NCT03881488 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.